Prognostic impact of TERT promoter mutation suggests its utility as a surrogate marker for 1p/19q codeletion in IDH mutated gliomas

被引：0
|
作者：
Arita, Hideyuki [1 ,2 ]
Ohio, Makoto [3 ]
Nakamura, Taishi [4 ]
Tamura, Kaoru [5 ]
Miyake, Yohei [6 ]
Saito, Kuniaki [7 ]
Tanaka, Shota [8 ]
Higuchi, Fumi [9 ]
Kanemura, Yonehiro [10 ]
Ichimura, Koichi [1 ]
机构：
[1] Natl Canc Ctr, Res Inst, Div Brain Tumor Translat Res, Tokyo, Japan
[2] Osaka Univ, Grad Sch Med, Div Neurosurg, Osaka, Japan
[3] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan
[4] Yokohama City Univ, Grad Sch Med, Dept Neurosurg, Yokohama, Kanagawa, Japan
[5] Tokyo Med & Dent Univ, Dept Neurosurg, Tokyo, Japan
[6] Saitama Med Univ Int Med Ctr, Dept Neurooncol Neurosurg, Saitama, Japan
[7] Kyorin Univ, Fac Med, Dept Neurosurg, Tokyo, Japan
[8] Univ Tokyo, Dept Neurosurg, Tokyo, Japan
[9] Dokkyo Med Univ, Dept Neurosurg, Mibu, Tochigi, Japan
[10] Natl Hosp Org, Osaka Natl Hosp, Inst Clin Res, Osaka, Japan
来源：
BRAIN PATHOLOGY | 2019年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：193 / 193
页数：1
相关论文
共 50 条
  • [21] Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors
    Mur, Pilar
    Mollejo, Manuela
    Ruano, Yolanda
    Rodriguez de Lope, Angel
    Fiano, Concepcion
    Fernando Garcia, Juan
    Castresana, Javier S.
    Hernandez-Lain, Aurelio
    Rey, Juan A.
    Melendez, Barbara
    ACTA NEUROPATHOLOGICA, 2013, 126 (02) : 277 - 289
  • [22] Impact of 1p/19q Codeletion and Histology on Outcomes of Anaplastic Gliomas Treated With Radiation Therapy and Temozolomide
    Speirs, Christina K.
    Simpson, Joseph R.
    Robinson, Clifford G.
    DeWees, Todd A.
    Tran, David D.
    Linette, Gerry
    Chicoine, Michael R.
    Dacey, Ralph G.
    Rich, Keith M.
    Dowling, Joshua L.
    Leuthardt, Eric C.
    Zipfel, Gregory J.
    Kim, Albert H.
    Huang, Jiayi
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (02): : 268 - 276
  • [23] Sensitive and specific detection of 1p/19q codeletion in gliomas by next generation sequencing
    Dubbink, E.
    Atmodimedjo, P. N.
    van Marion, R. M.
    Kros, J. M.
    van den Bent, M. J.
    Dinjens, W. N. M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 53 - 53
  • [24] Care Setting Disparities in 1p/19q Codeletion Testing Rates for Diffuse Gliomas
    Torre, Matthew
    Lamba, Nayan
    Gupta, Sneha
    Smith, Timothy
    Iorgulescu, J. Bryan
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1623 - 1625
  • [25] Multipool-CEST and CEST-based pH assessment as predictive tools for glioma grading, IDH mutation, 1p/19q codeletion, and MGMT promoter methylation in gliomas
    Zhang, Xinli
    Lu, Jue
    Liu, Xiaoming
    Sun, Peng
    Qin, Qian
    Xiang, Zhengdong
    Cheng, Lan
    Zhang, Xiaoxiao
    Guo, Xiaotong
    Wang, Jing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [26] SURVEY OF THE PROGNOSTIC FACTORS IN 1p/19q CODELETED GLIOMAS
    Hayashi, Saeko
    Sasaki, Hikaru
    Kimura, Tokuhiro
    Nakamura, Takumi
    Miwa, Tomoru
    Hirose, Yuichi
    Yoshida, Kazunari
    NEURO-ONCOLOGY, 2013, 15 : 89 - 90
  • [27] Care Setting Disparities in 1p/19q Codeletion Testing Rates for Diffuse Gliomas
    Torre, Matthew
    Lamba, Nayan
    Gupta, Sneha
    Smith, Timothy
    Iorgulescu, J. Bryan
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1623 - 1625
  • [28] Survival Risk Prediction Models of Gliomas Based on IDH and 1p/19q
    Zou, Han
    Li, Chang
    Wanggou, Siyi
    Li, Xuejun
    JOURNAL OF CANCER, 2020, 11 (15): : 4297 - 4307
  • [29] Efficient diagnosis of IDH-mutant gliomas: 1p/19qNET assesses 1p/19q codeletion status using weakly-supervised learning
    Kim, Gi Jeong
    Lee, Tonghyun
    Ahn, Sangjeong
    Uh, Youngjung
    Kim, Se Hoon
    NPJ PRECISION ONCOLOGY, 2023, 7 (01)
  • [30] Efficient diagnosis of IDH-mutant gliomas: 1p/19qNET assesses 1p/19q codeletion status using weakly-supervised learning
    Gi Jeong Kim
    Tonghyun Lee
    Sangjeong Ahn
    Youngjung Uh
    Se Hoon Kim
    npj Precision Oncology, 7
12345